Privacy Policy Disclaimer
  Advanced SearchBrowse




Journal Article

Phototherapy of Alzheimer’s Disease: Photostimulation of Brain Lymphatics during Sleep: A Systematic Review


Semyachkina-Glushkovskaya,  Oxana
External Organizations;

Penzel,  Thomas
External Organizations;

Poluektov,  Mikhail
External Organizations;

Fedosov,  Ivan
External Organizations;

Tzoy,  Maria
External Organizations;

Terskov,  Andrey
External Organizations;

Blokhina,  Inna
External Organizations;

Sidorov,  Viktor
External Organizations;


Kurths,  Jürgen
Potsdam Institute for Climate Impact Research;

External Ressource
No external resources are shared
Fulltext (public)

(Publisher version), 3MB

Supplementary Material (public)
There is no public supplementary material available

Semyachkina-Glushkovskaya, O., Penzel, T., Poluektov, M., Fedosov, I., Tzoy, M., Terskov, A., Blokhina, I., Sidorov, V., Kurths, J. (2023): Phototherapy of Alzheimer’s Disease: Photostimulation of Brain Lymphatics during Sleep: A Systematic Review. - International Journal of Molecular Sciences, 24, 13, 10946.

Cite as: https://publications.pik-potsdam.de/pubman/item/item_28956
The global number of people with Alzheimer’s disease (AD) doubles every 5 years. It has been established that unless an effective treatment for AD is found, the incidence of AD will triple by 2060. However, pharmacological therapies for AD have failed to show effectiveness and safety. Therefore, the search for alternative methods for treating AD is an urgent problem in medicine. The lymphatic drainage and removal system of the brain (LDRSB) plays an important role in resistance to the progression of AD. The development of methods for augmentation of the LDRSB functions may contribute to progress in AD therapy. Photobiomodulation (PBM) is considered to be a non-pharmacological and safe approach for AD therapy. Here, we highlight the most recent and relevant studies of PBM for AD. We focus on emerging evidence that indicates the potential benefits of PBM during sleep for modulation of natural activation of the LDRSB at nighttime, providing effective removal of metabolites, including amyloid-β, from the brain, leading to reduced progression of AD. Our review creates a new niche in the therapy of brain diseases during sleep and sheds light on the development of smart sleep technologies for neurodegenerative diseases.